NYSE:OGNPharmaceuticals
Positive Pediatric VTAMA Data Could Be a Game Changer for Organon (OGN)
Organon recently presented new results from a sub-analysis of pooled Phase 3 ADORING 1 and 2 trials of VTAMA cream in children with atopic dermatitis at the 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting, showing early and consistent skin clearance even for children with atopic comorbidities.
This clinical data underscores the potential expansion of VTAMA's use in pediatrics, enhancing Organon's dermatology pipeline and addressing an unmet need among young...